Publicación:
COVID-19 Vaccines, Healthcare Policies and Stock Markets: Are There Winners and Losers?

Vista sencilla de ítem
dc.contributor.authorDiaz, Ricardo F
dc.contributor.authorHerrador Alcaide, Teresa Carmen
dc.contributor.authorSánchez-Robles Rute, Blanca
dc.date.accessioned2024-12-10T08:49:53Z
dc.date.available2024-12-10T08:49:53Z
dc.date.issued2023-05-24
dc.descriptionLa versión registrada de este artículo, publicado por primera vez en Risk Manag Healthc Policy. 2023;16:971-989, está disponible en línea en el sitio web del editor: https://doi.org/10.2147/RMHP.S406216 The recorded version of this article, first published in Risk Management Healthc Policy. 2023; 16:971-989, available online at the publisher's website: https://doi.org/10.2147/RMHP.S406216
dc.description.abstractPurpose: This paper focuses on the stock market performance of a set of biopharmaceutical companies listed in the US stock exchange in response to news about the unfolding of the COVID pandemic and the development of COVID-19 vaccines. Methods: We analyze the short-term impact of some episodes by means of event analysis. We consider two categories of events: news related to the expansion of the pandemic and information about the development of COVID-19 vaccines. Results: We find that the impact during the first months of the pandemic news impacted the returns of the pharmaceutical firms, but the effect was not large, in general. The only exceptions are two small biotechnological firms, Moderna and Novavax, are exceptions since they registered large positive abnormal returns, which vanished over time. Encouraging announcements about the success of Phase III results had a positive impact the share prices of Pfizer, Moderna and Novavax. Our results also suggest that the emergency authorization provided by the US regulatory agency to the Pfizer vaccine was anticipated several days in advance and welcomed by the market. The announcement of a deal to supply vaccines between Moderna and the European Commission have generated large positive returns for this company. Conclusion: Our findings have policy implications. First, financial markets have supported and reinforced government strategies to fight the pandemic, characterized by funding of promising projects, building diversified vaccine portfolios and expediting approvals by regulatory agencies. Second, our findings suggest that not all drug developers have automatically obtained large profits from the design and manufacturing of COVID-19 vaccines, according to the behaviour of stock prices. These results cast doubts over attempts to discredit the efficacy of COVID-19 vaccines with the argument that they are primarily a means to obtain large and quick profits by pharmaceuticals, or than vaccination campaigns are driven by economic goals rather than by public health considerations.en
dc.description.versionversión publicada
dc.identifier.citationDiaz RF, Herrador-Alcaide TC, Sanchez-Robles B. COVID-19 Vaccines, Healthcare Policies and Stock Markets: Are There Winners and Losers?. Risk Manag Healthc Policy. 2023;16:971-989 https://doi.org/10.2147/RMHP.S406216
dc.identifier.doihttps://doi.org/10.2147/RMHP.S406216
dc.identifier.issn1179-1594
dc.identifier.urihttps://hdl.handle.net/20.500.14468/24782
dc.journal.issue3
dc.journal.titleRisk Management and Healthcare Policy
dc.journal.volume16
dc.language.isoen
dc.page.final989
dc.page.initial971
dc.publisherTaylor and Francis Group
dc.relation.centerFacultades y escuelas::Facultad de Ciencias Económicas y Empresariales
dc.relation.departmentAnálisis Económico
dc.relation.isreferencedbyhttps://doi.org/10.21950/UJFZPM
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.es
dc.subject53 Ciencias Económicas
dc.subject.keywordsevent analysisen
dc.subject.keywordsCOVID-19 vaccinesen
dc.subject.keywordsphase IIIen
dc.subject.keywordsclinical trialsen
dc.subject.keywordspharmaceutical industryen
dc.subject.keywordsstock marketsen
dc.titleCOVID-19 Vaccines, Healthcare Policies and Stock Markets: Are There Winners and Losers?en
dc.typeartículoes
dc.typejournal articleen
dspace.entity.typePublication
relation.isAuthorOfPublicationfd47b433-a0a5-46fb-8aab-a14aefca4bcd
relation.isAuthorOfPublication8572c8f0-e05c-4c6b-97c2-c6f535ff6698
relation.isAuthorOfPublication.latestForDiscoveryfd47b433-a0a5-46fb-8aab-a14aefca4bcd
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Sanchez_Robles_Blanca_COVID_19_Vaccines.pdf
Tamaño:
2.17 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
3.62 KB
Formato:
Item-specific license agreed to upon submission
Descripción:
Descargar
Colecciones
Artículos y papers